PDE6H — Phosphodiesterase 6H, cGMP-specific, cone, gamma

The PDE6H gene is responsible for producing a crucial part of an enzyme found in the cone cells of your eyes. Cone cells are the light-detecting cells in the retina that allow you to see colors and fine details in daylight. The enzyme, called cone-specific phosphodiesterase, acts like a switch that helps convert light entering your eye into electrical signals that your brain understands as vision. When there is a mutation in the PDE6H gene, this enzyme doesn't work properly or is missing. As a result, the cone cells cannot send the correct visual signals to the brain. This leads to a condition called achromatopsia, which causes partial or complete color blindness, poor vision in bright light, and sensitivity to light (photophobia). Because the rod cells (which handle night vision) are usually unaffected, people with this condition typically have normal vision in low light.

Gene description: The PDE6H gene provides instructions for making the inhibitory gamma subunit of the cone-specific phosphodiesterase enzyme. This enzyme is found exclusively in cone photoreceptor cells in the retina and is essential for normal color vision and visual acuity in bright light.

Patient and family guide: The PDE6H gene is responsible for producing a crucial part of an enzyme found in the cone cells of your eyes. Cone cells are the light-detecting cells in the retina that allow you to see colors and fine details in daylight. The enzyme, called cone-specific phosphodiesterase, acts like a switch that helps convert light entering your eye into electrical signals that your brain understands as vision. When there is a mutation in the PDE6H gene, this enzyme doesn't work properly or is missing. As a result, the cone cells cannot send the correct visual signals to the brain. This leads to a condition called achromatopsia, which causes partial or complete color blindness, poor vision in bright light, and sensitivity to light (photophobia). Because the rod cells (which handle night vision) are usually unaffected, people with this condition typically have normal vision in low light.

Gene function: PDE6H encodes the inhibitory gamma subunit of the cone-specific cGMP phosphodiesterase complex. It regulates the catalytic activity of the PDE6C alpha' subunits, keeping the enzyme inactive in the dark and allowing its activation upon light stimulation via transducin.

Protein structure: PDE6H is a small protein consisting of 83 amino acids. It contains conserved domains relevant for binding to transducin and inhibiting the catalytic activity of the phosphodiesterase complex.

Molecular function: In the cone phototransduction cascade, light-excited visual pigments activate transducin (GNAT2). Activated transducin binds to the PDE6H inhibitory gamma subunit, retracting it from the catalytic PDE6C alpha' subunits. This relieves the inhibition, allowing PDE6C to hydrolyze cGMP to 5'-GMP. The resulting decrease in intracellular cGMP concentration causes the closure of cGMP-gated cation channels (CNGA3/CNGB3), leading to membrane hyperpolarization and the generation of a visual signal.

Mutation spectrum: The mutation spectrum for PDE6H includes nonsense mutations, such as c.35C>G (p.Ser12*), which lead to a truncated, inactive protein or nonsense-mediated decay. Missense mutations and other sequence variants have also been observed.

Clinical significance: Mutations in the PDE6H gene cause a rare form of autosomal recessive achromatopsia (ACHM6) or incomplete achromatopsia. This disorder is characterized by severely reduced visual acuity, nystagmus, photophobia, and a severe color vision defect due to the loss of cone photoreceptor function.

Inheritance: Autosomal Recessive

Chromosomal location: 12q13

Research and therapeutic approaches: Currently, there is no approved cure for achromatopsia caused by PDE6H mutations. Management focuses on symptom relief using tinted contact lenses or glasses to reduce photophobia. Gene therapy approaches, which have shown promise in animal models for other achromatopsia genes (like CNGA3 and CNGB3), are an active area of research for PDE6H-related disease.